Download PDF
Neuropediatrics 2014; 45(02): 070-074
DOI: 10.1055/s-0034-1371508
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Epilepsy Genetics Revolutionizes Clinical Practice

Ingrid E. Scheffer
1   Department of Medicine, Florey Institute of Neurosciences and Mental Health, University of Melbourne, Austin Health, Melbourne, Australia
2   Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
10 March 2014 (online)

   Permissions and Reprints

See also:

Peter-Emil-Becker-Price 2013Neuropediatrics 2014; 45(02): 069-069
DOI: 10.1055/s-0034-1371548

Abstract

Objectives Epilepsy genetics has undergone a revolution in the past 19 years since the discovery of the first gene for epilepsy. The story of our increasing knowledge and how it impacts on patient care is presented with reference to recent discoveries. Understanding the significance of a genetic variant is challenging both in terms of molecular pathogenicity and in how this finding fits into the rubric of causation. In some cases, it may only be a contributing susceptibility factor; whereas in others, it explains the patient's disease.

Methods A brief overview of the clinicomolecular approaches is discussed in the context of the discovery of epilepsy genes. These include family studies and, more recently, next generation sequencing using multigene panels and whole exome sequencing.

Results Recent studies illustrating the way in which epilepsy genetics is changing clinical practice are described. A particular focus is DEPDC5, the first gene for nonlesional focal epilepsy likely to be relevant to sporadic patients with focal epilepsies and those from small families, in contrast to rare large families with autosomal dominant focal epilepsies. As DEPDC5 is a negative regulator of the mammalian target of rapamycin (mTOR) pathway, it is likely that some patients with DEPDC5 mutations may have malformations of cortical development akin to the two-hit hypothesis suggested in tuberous sclerosis. The greatest impact of epilepsy genetics at a clinical level is for patients with epileptic encephalopathies as many have de novo mutations—a rapidly expanding list of causative genes is being found.

Conclusion Epilepsy genetics is changing clinical practice enabling diagnosis in many patients, informing our understanding of comorbidities, prognosis, and genetic counseling. Importantly, a genetic finding may impact on treatment choices. At a biological level, new insights promise to lead to the development of novel therapies and bring together the seemingly disparate genetics of nonlesional epilepsies and epilepsies associated with cortical malformations.

Keywords

epilepsy - genetics - epilepsy syndromes - DEPDC5 - epileptic encephalopathies
 

  • References

  • 1 Chen Y, Lu J, Pan H , et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54 (2) 239-243
    CrossrefPubMedGoogle Scholar
  • 2 Heron SE, Phillips HA, Mulley JC , et al. Genetic variation of CACNA1H in idiopathic generalized epilepsy. Ann Neurol 2004; 55 (4) 595-596
    CrossrefPubMedGoogle Scholar
  • 3 Helbig I, Mefford HC, Sharp AJ , et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009; 41 (2) 160-162
    CrossrefPubMedGoogle Scholar
  • 4 de Kovel CG, Trucks H, Helbig I , et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 2010; 133 (Pt 1) 23-32
    CrossrefPubMedGoogle Scholar
  • 5 Dibbens LM, Mullen S, Helbig I , et al; EPICURE Consortium. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum Mol Genet 2009; 18 (19) 3626-3631
    CrossrefPubMedGoogle Scholar
  • 6 Scheffer IE, Grinton BE, Heron SE , et al. PRRT2 phenotypic spectrum includes sporadic and fever-related infantile seizures. Neurology 2012; 79 (21) 2104-2108
    CrossrefPubMedGoogle Scholar
  • 7 Arsov T, Mullen SA, Rogers S , et al. Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann Neurol 2012; 72 (5) 807-815
    CrossrefPubMedGoogle Scholar
  • 8 De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325 (10) 703-709
    CrossrefPubMedGoogle Scholar
  • 9 Steinlein OK, Mulley JC, Propping P , et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11 (2) 201-203
    CrossrefPubMedGoogle Scholar
  • 10 Wallace RH, Wang DW, Singh R , et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 1998; 19 (4) 366-370
    CrossrefPubMedGoogle Scholar
  • 11 Hildebrand MS, Dahl HHM, Damiano JA, Smith RJH, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet 2013; 50 (5) 271-279
    CrossrefPubMedGoogle Scholar
  • 12 Scheffer IE, Bhatia KP, Lopes-Cendes I , et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet 1994; 343 (8896) 515-517
    CrossrefPubMedGoogle Scholar
  • 13 De Fusco M, Becchetti A, Patrignani A , et al. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet 2000; 26 (3) 275-276
    CrossrefPubMedGoogle Scholar
  • 14 Aridon P, Marini C, Di Resta C , et al. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet 2006; 79 (2) 342-350
    CrossrefPubMedGoogle Scholar
  • 15 Scheffer IE, Bhatia KP, Lopes-Cendes I , et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 1995; 118 (Pt 1) 61-73
    CrossrefPubMedGoogle Scholar
  • 16 Derry CP, Heron SE, Phillips F , et al. Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disability. Epilepsia 2008; 49 (12) 2125-2129
    CrossrefPubMedGoogle Scholar
  • 17 Heron SE, Smith KR, Bahlo M , et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012; 44 (11) 1188-1190
    CrossrefPubMedGoogle Scholar
  • 18 Scheffer IE, Phillips HA, O'Brien CE , et al. Familial partial epilepsy with variable foci: a new partial epilepsy syndrome with suggestion of linkage to chromosome 2. Ann Neurol 1998; 44 (6) 890-899
    CrossrefPubMedGoogle Scholar
  • 19 Xiong L, Labuda M, Li DS , et al. Mapping of a gene determining familial partial epilepsy with variable foci to chromosome 22q11-q12. Am J Hum Genet 1999; 65 (6) 1698-1710
    CrossrefPubMedGoogle Scholar
  • 20 Klein KM, O'Brien TJ, Praveen K , et al. Familial focal epilepsy with variable foci mapped to chromosome 22q12: expansion of the phenotypic spectrum. Epilepsia 2012; 53 (8) e151-e155
    CrossrefPubMedGoogle Scholar
  • 21 Dibbens LM, de Vries B, Donatello S , et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013; 45 (5) 546-551
    CrossrefPubMedGoogle Scholar
  • 22 Callenbach PMC, van den Maagdenberg AMJM, Hottenga JJ , et al. Familial partial epilepsy with variable foci in a Dutch family: clinical characteristics and confirmation of linkage to chromosome 22q. Epilepsia 2003; 44 (10) 1298-1305
    CrossrefPubMedGoogle Scholar
  • 23 Berkovic SF, Serratosa JM, Phillips HA , et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia 2004; 45 (9) 1054-1060
    CrossrefPubMedGoogle Scholar
  • 24 Morales-Corraliza J, Gómez-Garre P, Sanz R, Díaz-Otero F, Gutiérrez-Delicado E, Serratosa JM. Familial partial epilepsy with variable foci: a new family with suggestion of linkage to chromosome 22q12. Epilepsia 2010; 51 (9) 1910-1914
    CrossrefPubMedGoogle Scholar
  • 25 Shaw RJ. Cell biology. GATORs take a bite out of mTOR. Science 2013; 340 (6136) 1056-1057
    CrossrefPubMedGoogle Scholar
  • 26 Bar-Peled L, Chantranupong L, Cherniack AD , et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340 (6136) 1100-1106
    CrossrefPubMedGoogle Scholar
  • 27 Carvill GL, Heavin SB, Yendle SC , et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013; 45 (7) 825-830
    CrossrefPubMedGoogle Scholar
  • 28 Carvill GL, Regan BM, Yendle SC , et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet 2013; 45 (9) 1073-1076
    CrossrefPubMedGoogle Scholar
  • 29 Allen AS, Berkovic SF, Cossette P , et al; Epi4K Consortium; Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. Nature 2013; 501 (7466): 217-221
    CrossrefPubMedGoogle Scholar
  • 30 Depienne C, Trouillard O, Gourfinkel-An I , et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 2010; 47 (6) 404-410
    CrossrefPubMedGoogle Scholar
  • 31 Dibbens LM, Tarpey PS, Hynes K , et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008; 40 (6) 776-781
    CrossrefPubMedGoogle Scholar